Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR‐RA) Study

托法替尼 医学 队列 类风湿性关节炎 危险系数 内科学 随机对照试验 置信区间
作者
Farzin Khosrow‐Khavar,Rishi Desai,Hemin Lee,Su Been Lee,Seoyoung C. Kim
出处
期刊:Arthritis & rheumatology [Wiley]
卷期号:74 (10): 1648-1659 被引量:41
标识
DOI:10.1002/art.42250
摘要

Results of the ORAL Surveillance safety trial have indicated that there is an increased risk for the development of malignancies with tofacitinib therapy when compared to treatment with tumor necrosis factor inhibitors (TNFi). This study was undertaken to further examine this safety concern in rheumatoid arthritis (RA) patients in a real-world setting.Using US insurance claims data from Optum Clinformatics (2012-2020), IBM MarketScan Research Databases (2012-2018), and Medicare (parts A, B, and D, 2012-2017), we created 2 cohorts of RA patients who had initiated treatment with tofacitinib or TNFi. The first cohort, designated the real-world evidence (RWE) cohort, included RA patients from routine care. For the second cohort, designated the randomized controlled trial (RCT)-duplicate cohort, we emulated the inclusion and exclusion criteria that were applied in the ORAL Surveillance trial of tofacitinib, which allowed us to assess the comparability of our results with the results of that trial. Cox proportional hazards models with propensity score fine-stratification weighting were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the risk of any malignancy (excluding nonmelanoma skin cancer). Database-specific estimates were meta-analyzed using fixed-effects models with inverse-variance weighting.The RWE cohort consisted of 83,295 patients, including 10,504 patients (12.6%) who received treatment with tofacitinib. The pooled weighted HR for the primary outcome of any malignancy associated with tofacitinib treatment compared to any malignancy associated with TNFi therapy was 1.01 (95% CI 0.83, 1.22) in the RWE cohort and 1.17 (95% CI 0.85, 1.62) in the RCT-duplicate cohort (compared to the ORAL Surveillance trial HR of 1.48 [95% CI 1.04, 2.09]).We did not find evidence of an increased risk of malignancy development with tofacitinib therapy, in comparison with TNFi therapy, in RA patients treated in a real-world setting. However, our results cannot rule out the possibility of an increase in risk that may accrue with a longer duration of treatment with tofacitinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助wzp采纳,获得10
刚刚
哈哈完成签到,获得积分20
1秒前
Xingliang_Wu98给深情怀亦的求助进行了留言
1秒前
2秒前
2秒前
小太阳完成签到,获得积分10
3秒前
哈哈发布了新的文献求助10
4秒前
4秒前
4秒前
星期八完成签到,获得积分10
4秒前
噗哈哈完成签到 ,获得积分10
5秒前
5秒前
mango发布了新的文献求助20
5秒前
5秒前
cctv18应助xiaoxiao采纳,获得10
5秒前
dengqin发布了新的文献求助10
6秒前
科研通AI2S应助dcr4328采纳,获得10
7秒前
小胡发布了新的文献求助10
7秒前
8秒前
xbchen完成签到,获得积分0
9秒前
10秒前
Sunny完成签到,获得积分10
11秒前
12秒前
12秒前
12秒前
钱浩发布了新的文献求助10
12秒前
Dwan完成签到 ,获得积分10
13秒前
yining关注了科研通微信公众号
13秒前
奶盖完成签到,获得积分10
13秒前
爱听歌早晨完成签到,获得积分10
14秒前
充电宝应助赫绮琴采纳,获得10
14秒前
_xySH发布了新的文献求助10
14秒前
14秒前
14秒前
14秒前
xiaoxiao发布了新的文献求助10
14秒前
丘比特应助小胡采纳,获得10
15秒前
15秒前
16秒前
16秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3054832
求助须知:如何正确求助?哪些是违规求助? 2711702
关于积分的说明 7427649
捐赠科研通 2356261
什么是DOI,文献DOI怎么找? 1247983
科研通“疑难数据库(出版商)”最低求助积分说明 606566
版权声明 596083